NRXP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 19.00%

Insider Buying (Last 12 Months): $46,800.00

Insider Selling (Last 12 Months): $0.00

NRx Pharmaceuticals Insider Trading History Chart

NRx Pharmaceuticals Share Price & Price History

^$2.44

▲ +0.03 (1.24%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

NRx Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2024	Jonathan C Javitt	Chairman	Buy	40,000	$1.17	$46,800.00	84,634
8/30/2023	Aaron Gorovitz	Director	Buy	3,500	$3.20	$11,200.00	10,500
8/22/2023	Jonathan C Javitt	Insider	Buy	20,000	$3.20	$64,000.00	34,633
12/16/2022	Stephen H Willard	CEO	Buy	5,000	$11.70	$58,500.00	5,000
12/16/2022	Voorhees Seth Van	CFO	Buy	3,000	$11.00	$33,000.00	4,633
12/7/2022	Jonathan C Javitt	Director	Sell	40,000	$10.00	$400,000.00	1,289,999

SEC Filings (Institutional Ownership Changes) for NRx Pharmaceuticals (NASDAQ:NRXP)

4.27% of NRx Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

NRx Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Anson Funds Management LP	2,025,104	$6.68M	0.6%	+26.2%	10.223%
11/14/2025	Two Sigma Investments LP	52,332	$0.17M	0.0%	+66.4%	0.264%
11/7/2025	Vanguard Group Inc.	534,956	$1.77M	0.0%	+18.3%	2.700%
11/5/2025	AdvisorShares Investments LLC	342,136	$1.13M	0.2%	+29.7%	1.727%
10/29/2025	One Wealth Management Investment & Advisory Services LLC	27,991	$92K	0.1%	+86.1%	0.141%
10/23/2025	Ethos Financial Group LLC	11,900	$39K	0.0%	N/A	0.060%
8/13/2025	Marshall Wace LLP	33,384	$0.11M	0.0%	-62.5%	0.193%
8/8/2025	Geode Capital Management LLC	172,255	$0.56M	0.0%	+27.9%	0.996%
8/4/2025	AdvisorShares Investments LLC	263,797	$0.86M	0.2%	-8.0%	1.526%
5/28/2025	Anson Funds Management LP	1,179,061	$2.42M	0.4%	+535.1%	6.820%
5/14/2025	Anson Funds Management LP	1,179,061	$2.42M	0.3%	+535.1%	6.845%
2/17/2025	Squarepoint Ops LLC	25,299	$56K	0.0%	N/A	0.161%
2/17/2025	Millennium Management LLC	27,624	$61K	0.0%	N/A	0.176%
2/17/2025	Anson Funds Management LP	185,660	$0.41M	0.0%	+30.3%	1.183%
2/14/2025	AdvisorShares Investments LLC	310,314	$0.68M	0.1%	+138.5%	1.977%
2/14/2025	Sassicaia Capital Advisers LLC	15,000	$33K	0.8%	N/A	0.096%
11/15/2024	Anson Funds Management LP	142,525	$0.24M	0.0%	N/A	1.326%
11/13/2024	Townsquare Capital LLC	15,041	$25K	0.0%	N/A	0.140%
8/8/2024	AdvisorShares Investments LLC	108,085	$0.28M	0.0%	-82.4%	1.010%
8/6/2024	One Wealth Management Investment & Advisory Services LLC	15,041	$37K	0.0%	-89.3%	0.141%
2/14/2024	AdvisorShares Investments LLC	642,632	$0.30M	0.1%	N/A	0.755%
1/25/2024	One Wealth Management Investment & Advisory Services LLC	140,402	$65K	0.0%	N/A	0.165%
11/15/2023	Sabby Management LLC	325,000	$84K	0.1%	-53.6%	0.398%
5/1/2023	Virtu Financial LLC	46,210	$30K	0.0%	N/A	0.065%
2/9/2023	HBK Sorce Advisory LLC	58,460	$65K	0.0%	N/A	0.086%
1/31/2023	AE Wealth Management LLC	29,515	$33K	0.0%	N/A	0.044%
1/27/2023	Exchange Traded Concepts LLC	26,924	$30K	0.0%	+154.0%	0.040%
1/18/2023	Exchange Traded Concepts LLC	26,924	$30K	0.0%	+154.0%	0.040%
11/3/2022	Texas Capital Bank Wealth Management Services Inc.	63,290	$47K	0.0%	N/A	0.094%
5/18/2022	Ursa Fund Management LLC	15,000	$37K	0.0%	N/A	0.023%
4/29/2022	United Asset Strategies Inc.	18,300	$45K	0.0%	N/A	0.027%
2/9/2022	Wolverine Asset Management LLC	37,105	$0.18M	0.0%	-12.8%	0.063%
2/8/2022	Raymond James Financial Services Advisors Inc.	11,567	$55K	0.0%	N/A	0.020%
11/15/2021	Penserra Capital Management LLC	2,956	$27K	0.0%	N/A	0.005%
11/12/2021	Wolverine Asset Management LLC	42,568	$0.39M	0.0%	+118.4%	0.079%
11/5/2021	Advisor Group Holdings Inc.	42,885	$0.40M	0.0%	+1,197.6%	0.080%
11/2/2021	Cambridge Investment Research Advisors Inc.	153,523	$1.42M	0.0%	N/A	0.285%

Data available starting January 2016

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Today's Range

Now: $2.44

$2.36

$2.51

50 Day Range

MA: $2.83

$2.03

$3.67

52 Week Range

Now: $2.44

$1.15

$6.01

Volume

356,150 shs

Average Volume

436,705 shs

Market Capitalization

$68.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Who are the company insiders with the largest holdings of NRx Pharmaceuticals?: NRx Pharmaceuticals' top insider investors include:
Jonathan C Javitt (Chairman)
Learn More about top insider investors at NRx Pharmaceuticals.
Who are the major institutional investors of NRx Pharmaceuticals?: NRx Pharmaceuticals' top institutional investors include:
Anson Funds Management LP — 10.22%
Vanguard Group Inc. — 2.70%
AdvisorShares Investments LLC — 1.73%
Two Sigma Investments LP — 0.26%
One Wealth Management Investment & Advisory Services LLC — 0.14%
Ethos Financial Group LLC — 0.06%
Learn More about top institutional investors of NRx Pharmaceuticals stock.
Which institutional investors are selling NRx Pharmaceuticals stock?: In the previous quarter, NRXP stock was sold by these institutional investors:
Group One Trading LLC
Which institutional investors are buying NRx Pharmaceuticals stock?: In the previous quarter, NRXP stock was bought by institutional investors including:
Anson Funds Management LP
Vanguard Group Inc.
AdvisorShares Investments LLC
Two Sigma Investments LP
One Wealth Management Investment & Advisory Services LLC
Ethos Financial Group LLC